S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
BREAKING: Tiny biotech successfully treats blindness (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
BREAKING: Tiny biotech successfully treats blindness (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Stock market today: Global shares mostly decline, while Tokyo again finishes at a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
BREAKING: Tiny biotech successfully treats blindness (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
BREAKING: Tiny biotech successfully treats blindness (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Stock market today: Global shares mostly decline, while Tokyo again finishes at a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
BREAKING: Tiny biotech successfully treats blindness (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
BREAKING: Tiny biotech successfully treats blindness (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Stock market today: Global shares mostly decline, while Tokyo again finishes at a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
BREAKING: Tiny biotech successfully treats blindness (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
BREAKING: Tiny biotech successfully treats blindness (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Stock market today: Global shares mostly decline, while Tokyo again finishes at a record high
AT&T will give $5 to customers hit by cellphone network outage

C4 Therapeutics (CCCC) Earnings Date, Estimates & Call Transcripts

$8.99
+0.19 (+2.16%)
(As of 02/23/2024 08:52 PM ET)
Skip Charts & View Estimated and Actual Earnings Data

CCCC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CCCC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

C4 Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.43)($0.43)($0.43)
Q2 20241($0.53)($0.53)($0.53)
Q3 20241($0.34)($0.34)($0.34)
Q4 20241($0.65)($0.65)($0.65)
FY 20244($1.95)($1.95)($1.95)

CCCC Earnings Date and Information

C4 Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

C4 Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
11/1/2023Q3 2023($0.65)($0.55)+$0.10($0.55)$6.94 million$11.07 million
8/8/2023Q2 2023($0.74)($0.73)+$0.01($0.73)$8.65 million$2.66 million
5/4/2023Q1 2023($0.78)($0.71)+$0.07($0.71)$6.71 million$3.76 million
2/23/2023Q4 2022($0.72)($0.76)($0.04)($0.76)$8.56 million$2.85 million
11/3/2022Q3 2022($0.65)($0.65)-($0.65)$9.72 million$6.75 million
8/4/2022Q2 2022($0.68)($0.56)+$0.12($0.56)$7.79 million$13.83 million
5/5/2022Q1 2022($0.61)($0.65)($0.04)($0.65)$7.67 million$7.65 million
2/24/2022Q4 2021($0.59)($0.31)+$0.28($0.31)$7.16 million$20.08 million    
11/10/2021Q3 2021($0.57)($0.51)+$0.06($0.51)$7.28 million$8.50 million
8/10/2021Q2 2021($0.59)($0.51)+$0.08($0.51)$7.45 million$9.78 million
5/13/2021Q1 2021($0.63)($0.49)+$0.14($0.49)-$7.43 million












C4 Therapeutics Earnings - Frequently Asked Questions

When is C4 Therapeutics's earnings date?

C4 Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on CCCC's earnings history.

How much revenue does C4 Therapeutics generate each year?

C4 Therapeutics (NASDAQ:CCCC) has a recorded annual revenue of $20.76 million.

How much profit does C4 Therapeutics generate each year?

C4 Therapeutics (NASDAQ:CCCC) has a recorded net income of -$128.18 million. CCCC has generated -$2.67 earnings per share over the last four quarters.

What is C4 Therapeutics's EPS forecast for next year?

C4 Therapeutics's earnings are expected to grow from ($2.28) per share to ($2.14) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:CCCC) was last updated on 2/26/2024 by MarketBeat.com Staff